/ News, Research
TBVAC-HORIZON kicks off (King Lab and Pinschewer Lab)
The Horizon Europe programme has funded the TBVAC-HORIZON project to improve the understanding of lung immunity to tuberculosis infection and to establish a diversified innovative TB vaccine pipeline targeting mucosal immunity. The King and Pinschewer labs @DBM are one of the 19 partners for the project that will be coordinated by the Tuberculosis Vaccine Initiative and will run for 4 years.
We would like to congratulate Prof. Dr. Carolyn King and Prof. Dr. Daniel Pinschewer. We wish you good cooperation and success.